Table 1.
Characteristics of the included studies.
Autdor, Year |
Study Design |
Mean Age (years) |
Female (%) |
Duration of PHN |
Pain Intensity |
Body Area |
Follow-up |
Pain Scale |
Ashok, 201622 | Double-blind RCT | 60.17 | 43.30 | >3 months | VAS ≥30 mm | T3–T11 | 8 weeks | VAS |
Dan, 201817 | RCT | 67 | – | >1 month | – | Cervical or thoracolumbar | 12 hours | VAS |
Dong, 201719 | Single-blind RCT | 69.98 | 69.70 | >3 months | – | Abdominal and thoracic back | 48 hours | VAS |
Gang, 201323 | RCT | 66.93 | 52.04 | 1 month–3 months | NRS ≥4 | – | 4 weeks | NRS |
Guo, 201324 | RCT | 57.06 | 47.06 | >1 month | – | – | 4 weeks | VAS |
Ji, 201225 | RCT | 63.5 | 40 | – | – | Chest and back | 8 weeks | VAS |
Lizu, 201026 | Double-blind RCT | 67.33 | 53.33 | >3 months | VAS ≥5 | Orofacial, cervical and upper extremity, lumbar and lower extremity | 3 months | VAS |
Ma, 201320 | Double-blind RCT | 72.16 | 50.00 | ≥6 months | VAS >30 mm | T2–T11 | 6 months | VAS |
Mohamed, 201821 | Double-blind RCT | 58.74 | 44.19 | >6 months | VAS >30 mm | T2–T11 | 1 year | VAS |
Wang, 201218 | RCT | 67.2 | 44.23 | >3 months | VAS >6 | Thoracic and back | 12 weeks | VAS |
Xia, 201816 | RCT | 66.47 | 50.0 | 4 months–3 years | – | Abdominal and thoracic area | 12 weeks | NRS |
Zoe, 201327 | Double-blind RCT | 75.35 | 40% | ≥3 months | VAS ≥7 | Thoracic, sciatic, brachial plexus | 20 weeks | VAS |
Autdor, Year |
Evaluation time point |
Basic Drugs |
N |
Groups, n |
Dose |
Route |
Adverse events related to interventional treatment |
|
Ashok, 201622 | Basic, 1 week, 2 weeks, 4 weeks, 8 weeks | Pregabalin; tramadol as rescue | 60 | PRF, 30; sham, 30 | 42°, 180 s; - | Intercostal | 2 local site reactions; 2 local site reactions | |
Dan, 201817 | Basic, 12 hours after treatment | Gabapentin; tramadol | 60 | Conventional puncture, 15; NB, 15; PRF, 15; PRF+NB, 15 | -; mecobalamin 1 mg/mL, extract from rabbit skin inflamed by vaccinia virus for injection 6 mL, 1% ropivacaine 2 mL; 0.9% normal saline 11 mL; 42°, 100 s × 3; PRF followed by NB | Paravertebral | None | |
Dong, 201719 | Basic, 48 hours after treatment | Pregabalin; diclofenac; cobamamide | 32 | Control, 18; PRF + NB + SC, 15 | -; 42°, 120 s × 2 + 5 mL (lidocaine + ropivacaine + betamethasone + cobamamide + NS) | DRG+SC | - | |
Gang, 201323 | Basic, 1 week, 2 weeks, 4 weeks | Gabapentin or pregabalin | 98 | MeB12 injection, 33; oral MeB12, 33; SC lidocaine injection, 32 | 1 mg MeB12; 0.5 mg MeB12 t.i.d.; 1% lidocaine | SC; oral; SC | - | |
Guo, 201324 | Basic, 4 weeks | Gabapentin, ibuprofen codeine, Vitb12 | 80 | SC + oral MeB12, 20; SC + IM MeB12, 19; paravertebral block + SC, 20; paravertebral block + O3 injection + SC, 21; | Ropivacaine 10 mg + betamethasone 1 mg + NS 20 mL; ropivacaine 10 mg+ betamethasone 1 mg + NS 20 mL; Ropivacaine 10 mg + betamethasone 1 mg + NS 20 mL; ropivacaine 10 mg + betamethasone 1 mg + NS 20 mL + O3 35 μg/mL | SC; SC; paravertebral; paravertebral | - | |
Ji, 201225 | Basic, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks | Pregabalin, celecoxib as rescue | 120 | SGB, 40; Pregabalin, 40; SGB + pregabalin, 40 | 0.5% lidocaine 10 mL; -; 0.5% lidocaine 10 mL | SGB | 1 hoarseness, 1 hematoma; -; 2 hoarseness, 1 hematoma | |
Lizu, 201026 | Basic, 1 day, 7 days, 3 months | Opioid as rescue | 60 | BTX-A, 20; Lidocaine, 20; placebo, 20 | 5 IU/mL (100 IU in total) BTX-A; 0.5% lidocaine; NS | SC | None | |
Ma, 201320 | Basic, 3 days, 1 weeks, 2 weeks, 1 month, 2 months, 3 months, 6 months | Gabapentin; antidepressants; tramadol | 92 | PRF, 46; sham, 46 | 42°, 120 s × 2; - | Intercostal | 1 bradycardia; 1 needle injury | |
Mohamed, 201821 | Basic, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, 14 weeks, 16 weeks, 18 weeks, 20 weeks, 22 weeks, 6 months, 9 months, 12 months | Pregabalin; acetaminophen as rescue | 43 | PRF, 21; sham, 22 | 42°, 120 s × 2; - | Intercostal | None | |
Wang, 201218 | Basic, 1 weeks, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks | Pregabalin | 52 | Thoracic paravertebral nerve block, 27; only drug, 25 | 0.3% lidocaine 10 mL + triamcinolone 10 mg; - | Paravertebral | None | |
Xia, 201816 | Basic, 2 weeks, 4 weeks, 12 weeks | Gabapentin | 60 | Acupuncture trigger point, 20; continuous epidural nerve block, 20; selective DRG PRF, 20 | -; 2 mL/hour (ropivacaine 225 mg + betamethasone + cobamamide + NS); 42° 10 minutes with an interval of 15 s | -; epidural; DRG | - | |
Zoe, 201327 | Basic, every day in the first 2 weeks, 4 weeks, 6 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks | Paracetamol | 30 | BTX-A, 15; NS, 15 | 100 IU + 4 mL NS; 4 mL NS only | SC; SC | None |
RCT, random controlled trial; PRF, pulsed radiofrequency; NB, nerve block; SC, subcutaneous injection or local infiltration; O3, ozone injection; SGB, stellate ganglion block; BTX-A, botulinum toxin type A; DRG, dorsal root ganglion; NS, normal saline; T, thoracic nerve; VAS, visual analog scale; NRS, numerical rating scale; IM, intramuscular; t.i.d., three times daily; -, data not available from the original article.